A start-up company founded by a University of Dundee researcher has been announced as the delivery partner for a £1 million ...
Rosalind Franklin University announced today that Dr. Joanne Kwak-Kim, director of the university's Reproductive Medicine and Immunology program and professor of obstetrics and gynecology, will be a ...
5hon MSN
In drug trials, lack of oversight of research ethics boards could put Canadian patients at risk
New drug approvals by Health Canada are based on the results of clinical trials. But before clinical trials can go ahead, ...
OrganBio today announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along with institutional investors IndieBio, ...
iOrganBio today announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along with institutional investors IndieBio ...
Latest center in international network established to accelerate clinical breakthroughs in maternal and infant health launches in Texas, home to one of ...
The Daily Galaxy on MSN
A Flaw at Last? AI Just Detected Something in Cancer Cells That Doctors Overlooked for Years
In a dedicated lab at Yale University and a data center deep inside Google DeepMind, a team of researchers may have just ...
Summary of the Annual Scientific Meeting (ASM) of the Irish Pain Society (IPS) on October 18, 2025, University of Galway by ...
(NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care ...
Zeiss has entered into a partnership with the University of Galway that will enable the college to use groundbreaking imaging technology.
Antimicrobial resistance (AMR) is one of the world’s most urgent health challenges, with the WHO’s new report showing there are ‘too few antibacterials in the pipeline’. Most of the ‘low-hanging fruit ...
Zacks.com on MSN
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results